Patents by Inventor Sofiya Micheva-Viteva

Sofiya Micheva-Viteva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIV-1 latency model for high throughput screening
    Patent number: 9017935
    Abstract: Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: April 28, 2015
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventors: Joseph P. Dougherty, Sofiya Micheva-Viteva, Stuart W. Peltz, Yacov Ron, Annmarie Pacchia
  • HIV-1 LATENCY MODEL FOR HIGH THROUGHPUT SCREENING
    Publication number: 20130040385
    Abstract: Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope.
    Type: Application
    Filed: July 17, 2012
    Publication date: February 14, 2013
    Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
    Inventors: Joseph P. Dougherty, Sofiya Micheva-Viteva, Stuart W. Peltz, Yacov Ron, Annmarie L. Pacchia
  • HIV-1 latency model for high throughput screening
    Patent number: 8247167
    Abstract: Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope.
    Type: Grant
    Filed: November 27, 2006
    Date of Patent: August 21, 2012
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventors: Joseph P. Dougherty, Sofiya Micheva-Viteva, Stuart W. Peltz, Yacov Ron, Annmarie L. Pacchia
  • HIV-1 LATENCY MODEL FOR HIGH THROUGHPUT SCREENING
    Publication number: 20090305227
    Abstract: Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope.
    Type: Application
    Filed: November 27, 2006
    Publication date: December 10, 2009
    Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
    Inventors: Joseph P. Dougherty, Sofiya Micheva-Viteva, Stuart W. Peltz, Yacov Ron, Annmarie L. Pacchia